Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04685317Recruiting
Sentinel brain-protection device during atrial fibrillation ablation
This trial tests whether a specialized “brain protection” device can improve safety during atrial fibrillation (AF) catheter ablation. It may help reduce the risk of stroke or related complications while treating AF.
Rochester, MinnesotaAges 18 years+ - NCT07482657RecruitingPhase 2
Zelicapavir for RSV in infants and toddlers
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
BangkokAges 4 weeks–3 years - NCT06798363RecruitingPhase 2/Phase 3
Testing different doses of propranolol for ulcerated hemangioma in children.
This trial tests different starting doses of oral propranolol to see which works best and is safest for treating infantile hemangiomas that have ulcers (sores). It may help your child heal faster.
Chengdu, SichuanAges 1 month–4 years - NCT05421858RecruitingPhase 3
Study drug for adults with bloodstream or deep Candida infection
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
Birmingham, AlabamaAges 18 years+ - NCT07710157RecruitingPhase 2
Obinutuzumab for first episode of minimal change disease
This trial tests if obinutuzumab, a targeted therapy, can safely and effectively treat adults with their first episode of minimal change disease (MCD), a kidney condition causing protein leakage. Participants will receive the drug to see if it reduces protein in urine and improves symptoms.
GrazAges 18 years+ - NCT07680946RecruitingPhase 2
Testing ublituximab for treatment-resistant schizophrenia
This trial tests an experimental drug, ublituximab, to see if it helps people with schizophrenia that hasn't gotten better with standard treatments. It may offer a new option for those who still have significant symptoms despite current therapy.
Little Rock, ArkansasAges 18–60 - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+ - NCT07243639Recruiting
Etrasimod for elderly patients with ulcerative colitis
This trial tests an oral medication called etrasimod for elderly patients with active ulcerative colitis. It aims to see if the drug is safe and effective in reducing inflammation and symptoms.
Komagane, NaganoAges Any age - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Birmingham, AlabamaAges 16–75 - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07288567RecruitingPhase 3
KarXT for teens with schizophrenia
This trial tests if a new medicine, KarXT, can safely and effectively treat schizophrenia in adolescents. It may help teenagers who have active symptoms like hallucinations or disorganized thinking.
Anaheim, CaliforniaAges 13–17 - NCT06951711RecruitingPhase 3
KarXT for mania in bipolar I disorder
This study tests a new medication called KarXT to see if it helps calm manic episodes in people with bipolar I disorder. You would need to be in the hospital for a manic episode and stop other psychiatric medications temporarily.
Little Rock, ArkansasAges 18–65 - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Ramat GanAges 1–30 - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT07054515RecruitingPhase 3
Study of oral nizubaglustat for rare genetic disorders
This trial tests a new oral medicine, nizubaglustat (AZ-3102), for children and adults (4+) with late-infantile or juvenile Niemann-Pick type C, GM1, or GM2 gangliosidosis. It aims to see if the drug is safe and helps slow disease progression.
Oakland, CaliforniaAges 4 years+ - NCT06932263RecruitingPhase 2
Testing tozorakimab for uncontrolled asthma
This trial tests a new drug called tozorakimab for adults whose asthma is not well controlled despite using medium-to-high dose inhaled steroids. The study aims to find the best dose and see if it reduces asthma attacks.
Bakersfield, CaliforniaAges 18–75 - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+ - NCT07711171RecruitingPhase 4
Canagliflozin for type 2 diabetes with mild memory problems
This trial tests whether the diabetes drug canagliflozin can help people with type 2 diabetes and mild cognitive impairment. It may slow down memory and thinking problems while also improving blood sugar control.
Shanghai, Shanghai MunicipalityAges 40–75 - NCT07419828RecruitingPhase 3
Study of HRS-1780 for chronic kidney disease
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
Nanjing, JiangsuAges 18–80 - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT07332091RecruitingPhase 2
Testing vamifeport for iron overload in hereditary hemochromatosis
This trial tests an oral medication, vamifeport, to reduce iron buildup in people with hereditary hemochromatosis caused by the HFE gene. It may offer a new treatment option to manage iron levels without frequent phlebotomy.
Gilbert, ArizonaAges 18 years+ - NCT07219420RecruitingPhase 3
Study of bimekizumab for palmoplantar pustulosis
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
Birmingham, AlabamaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.